Lunai Bioworks Inc.
RENB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $3 | $4 | $8 |
| G&A Expenses | $18 | $24 | $15 | $14 |
| SG&A Expenses | $18 | $25 | $15 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $171 | $54 | $0 | $0 |
| Operating Expenses | $189 | $82 | $20 | $23 |
| Operating Income | -$189 | -$82 | -$39 | -$116 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $11 | $1 | -$1 | $3 |
| Pre-Tax Income | -$178 | -$81 | -$40 | -$113 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$178 | -$81 | -$40 | -$113 |
| % Margin | – | – | – | – |
| EPS | -1.08 | -8.4 | -7.1 | -21.6 |
| % Growth | 87.1% | -18.3% | 67.1% | – |
| EPS Diluted | -1.08 | -8.4 | -7.1 | -21.6 |
| Weighted Avg Shares Out | 165 | 10 | 6 | 5 |
| Weighted Avg Shares Out Dil | 165 | 10 | 6 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$1 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$189 | -$80 | -$39 | -$113 |
| % Margin | – | – | – | – |